Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck (MRK) has been one of the stocks most ... (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company developing innovative cancer therapies, today presented ...

In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The stock's fall snapped a five-day winning streak.

Shares of Merck & Co. Inc. MRK inched 0.53% higher to $115.86 Friday, on what proved to be an all-around positive trading ...

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

First thing first, we like that Merck has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 21% which is quite remarkable. However, we are curious as ...

now accounting for more than a third of its total sales there has been pressure on the company to diversify. Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.